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Association between IL28B polymorphism and treatment response
in patients with genotype 4 chronic hepatitis C
To the Editor:
We read with interest the study by Asselah et al. published in
the Journal of Hepatology [1] on the impact of IL28B SNPs on
the outcome of antiviral therapy in HCV genotype 4 patients
showing a signiﬁcant and independent association between
the polymorphism in rs12979860 of the IL28B gene and the
treatment response in a cohort of 82 consecutive treatment-
naïve patients. In the discussion, the authors surprisingly state
that to the best of their knowledge this was the ﬁrst study to
examine this association in this speciﬁc group of patients with
HCV-4 infection.
In fact, we already published a study that shows this corre-
lation more than a year ago [2]. Apparently the authors missed
our well published study since they even do not quote it. In
our study, 102 treatment-naïve HCV-4 infected patients (91
male, 11 female; age: 40.6 ± 8.2; 99 Egyptian, 3 European;
advanced ﬁbrosis [METAVIR F3–4]: 33.3%) were investigated.
Together with the rs12979860, we also determined the
rs8099917 SNP. We showed a signiﬁcant association between
the beneﬁcial IL28B CC genotype and sustained virologic
response (SVR), rapid virologic response (RVR), and 24-h
decline in viral load after the ﬁrst dose of peginterferon. In a
multivariate logistic regression model adjusting for age, BMI,
baseline viral load, and advanced ﬁbrosis, we identiﬁed IL28B
genotype, advanced ﬁbrosis, and high baseline viral load as
independent pre-treatment risk factors for SVR (Table 1). Thus,
when RVR was included in the multivariate model, only RVR
(OR: 27.25, 95% CI: 5.981–124.19; p <0.0001) and advanced
ﬁbrosis (OR: 0.168, 95% CI: 0.042–0.669; p = 0.0115) remained
signiﬁcant.
Furthermore, we extended our observation to the early phase
of virus elimination. We showed a faster decline of HCV viral load
after 24 h in CC carriers in a subgroup analysis of 39 patients (CC
[n = 18]: 1.599 ± 0.589 log10 IU/ml, TC/TT [n = 21]: 0.766 ± 0.547
log10 IU/ml; p <0.001).
In summary, we presented more data in more patients than in
the study by Asselah, which is only conﬁrmatory and certainly
not novel information.
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Table 1. Univariate and multivariate logistic regression analysis of factors affecting SVR in patients with genotype 4.
Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Age (10 yr increment)
Advanced fibrosis (F3/4)
0.533 0.306-0.926 0.0256
BMI (1.0 kg/m² increment) 1.013 0.982-1.046 0.41
High baseline viral load (>800.000 IU/ml) 0.292 0.092-0.934 0.038 0.064 0.008-0.496 0.0085
0.278 0.104-0.744 0.011 0.209 0.066-0.660 0.0076
IL28B (T allele) 0.136 0.047-0.394 0.0002 0.124 0.030-0.505 0.0036
Reply to ‘‘Association between IL28B polymorphism and
treatment response in patients with genotype 4 chronic hepatitis C’’
HCV genotype 4 infection: A major medical need
To the Editor:
Indeed, genotype 4 (HCV-4) is the most frequent cause of chronic
hepatitis C in the Middle-East, and sub-Saharan Africa. It has
recently spread to Southern Europe, particularly among intrave-
nous drug users and immigrants [1]. HCV-4 is mainly found in
Egypt, the country with the highest prevalence of HCV worldwide
(15%), where HCV-4 represents 90% of all HCV cases. For geno-
type 4 infected patients, the most effective therapy to eradicate
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